Stoke Therapeutics and Biogen to present zorevunersen clinical data
Stoke Therapeutics and Biogen announced presentations of clinical data on zorevunersen for Dravet syndrome at the 16th European Epilepsy Congress (EEC).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.